US 11,992,492 B2
Composition for preventing or treating cellular senescence-associated diseases, containing homoharringtonine as active ingredient
Jae-Ryong Kim, Daegu (KR); Eok-Cheon Kim, Wonju-si (KR); Kyong-Jin Jung, Daegu (KR); Bum-Ho Bin, Hwaseong-si (KR); and You Lim Son, Daegu (KR)
Assigned to RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY, Gyeongsan-si (KR)
Appl. No. 17/413,101
Filed by RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY, Gyeongsan-si (KR)
PCT Filed Oct. 11, 2019, PCT No. PCT/KR2019/013371
§ 371(c)(1), (2) Date Jun. 11, 2021,
PCT Pub. No. WO2020/122391, PCT Pub. Date Jun. 18, 2020.
Claims priority of application No. 10-2018-0161042 (KR), filed on Dec. 13, 2018.
Prior Publication US 2022/0023309 A1, Jan. 27, 2022
Int. Cl. A61K 31/55 (2006.01); A61P 13/12 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/55 (2013.01) [A61P 13/12 (2018.01); A61P 29/00 (2018.01)] 4 Claims
 
1. A method of treating a renal cell cancer and a renal fibrosis comprising administering a pharmaceutical composition comprising homoharringtonine as an active ingredient to a subject in need of the treating the renal cell cancer and the renal fibrosis,
wherein the renal cell cancer and the renal fibrosis are induced by a renal ischemia-reperfusion injury.